主要研究方向
1. 主动靶向给药系统研究:以肿瘤靶向为目标,设计新型纳米微粒给药系统,实现化疗药物的定位、可控释放,并探讨其抗肿瘤作用的机制。
2. 功能性高分子载体研究:设计环境响应型(包括pH、温度、光敏感、还原响应等)生物可降解高分子材料及非病毒高分子基因载体,实现药物或基因的高效输送。
3. 治疗性基因递送研究:以具主动靶向的纳米微粒为载体,将具治疗性的外源重组基因或核酸定向导入至肿瘤细胞内,以诱导肿瘤细胞的凋亡,并探讨其作用机理。
课题组组长简介
陈大为 教授 博导
毕业于沈阳药科大学,分别获学士、硕士、博士学位,现任苏州大学药学院特聘教授,2011年受聘为山东省泰山学者—药学特聘专家 。
完成科研项目情况
1. 国家十一五重大专项(2009ZX09102-113 ): 抗癌 创新中药葫芦素B及其制剂新药临床前研究,2009-2011,339万元
2. 国家十一五支撑计划(2006BAI09B08-04):中药pH梯度依赖型多元定位释药微丸的研究,2006-2010,38万元
3. 国家十一五支撑计划(2007BAI46B07):维生素(复合维生素)高端制剂技术创新研究,2008-2010,150万元
在研科研项目情况
1. 国家自然科学基金(81173004):肿瘤细胞核靶向p53基因聚酰胺-胺聚合物递送系统的研究,2012-2015,50万元
2. 国家自然科学基金(30873181):配体介导的pH敏感聚酰胺-胺聚离子复合胶束的研究,2009-2011,30万元
3. 国家自然科学基金(30801456):新型温度/pH双敏自组装嵌段共聚物及其载药系统的研究,2009-2011,21万元
4. 辽宁省科技厅计划项目:可触发释药PLGA-PEG-PLGA接枝共聚物载体的研究,2011-2013,7万元
5. 河北省自然科学基金 :叶酸介导温度/pH双敏聚合物多西他赛胶束的研究 ,2011-2013,10万元
6. 苏州市科技计划项目:注射用多西他赛人工重组白蛋白纳米粒研究,2011-2014,20万元
新药研发项目情况
1. 注射用复方头孢氟辛钠/舒巴坦那,化药一类,已申报临床, 180万元
2. 尼非伟罗原料及片剂,化药一类,已获临床批文,1280万元
3. 注射葫芦素B冻干脂质体,中药一类,临床前研究,719万元
4. 核桃楸素注射液,中药一类,临床前研究, 240万元
5. 注射用全效复合维生素脂微球,化药三类,临床前研究, 250万元
6. 注射用多西他赛白蛋白纳米粒,化药三类,临床前研究, 530万元
1. Ying YS, Chen DW, Qiao MX, Lu Z, Hu HY. Preparation and evaluation of lectin-conjugated PLGA nanoparticles for oral delivery of thymopentin. J Controlled Release, 2006, 116: 337-345.
2. Jin Y, Ai P, Xin R, Chen DW. (2008) Morphological transformation of self-assembled nanostructures prepared from cholesteryl acyl didanosine and the optimal formulation of nanoparticulate systems: effects of solvents, acyl chain length and poloxamer 188. J Colloid Interface Sci. 326(1): 275-282.
3. Cheng MB, Wang JC, Li YH, Liu XY, Zhang X, Chen DW, Zhou SF, Zhang Q. Characterization of water-in-oil microemulsion for oral delivery of earthworm fibrinolytic enzyme. Journal of Controlled Release, 2008, 129(1): 41-48.
4. Niu ZQ, Chen FJ, Sun J, Liu XH, Wang YJ, Chen DW, He ZG. High-performance liquid chromatography for the determination of 3-n-butylphthalide in rat plasma by tandem quadrupole mass spectrometry: Application to a pharmacokinetic study. J Chromatography B, 2008, 870(1): 135-139.
5. Ying YS, Chen DW, Qiao MX, Lu Z, Hu HY. Preparation and evaluation of lectin-conjugated PLGA nanoparticles for oral delivery of thymopentin. J. of Controlled Release, 2006, 116: 337-345.
6. Sun Y, Wang JC, Zhang X, Zhang ZJ, Zheng Y, Chen DW, Zhang Q. Synchronic release of two hormonal contraceptives for about one month from the PLGA microspheres: In vitro and in vivo studies. J Controlled Release, 2008, 129(3): 192-199.
7. Wang WY; Zhao XL; Hu HY; Chen DW; Gu JC; Deng YH; Sun J. Galactosylated solid lipid nanoparticles with cucurbitacin B improves the liver targetability. Drug Delivery, 2010, 17(3): 114-122.
8. Jin YG; Qi NN; Tong L; Chen DW. Self-assembled drug delivery systems. Part 5: Self-assemblies of a bolaamphiphilic prodrug containing dual zidovudine. Iternational J Pharmaceutics, 2010, 386: 268-274.
9. Wang SN; Xu H; Xu JH; Zhang Y; Liu YC; Deng YH; Chen DW. Sustained Liver Targeting and Improved Antiproliferative Effect of Doxorubicin Liposomes Modified with Galactosylated Lipid and PEG-Lipid. AAPS Pharmscitech, 2010, 11(2):870-877.
陈大为课题组主要成员
程亮,博士,讲师。2010年毕业于上海交通大学药学院,从事高分子材料的设计与合成、药物的体内外作用及药理机制的研究 。
1. Cheng L, Guo S, Wu W. Characterization and in vitro release of praziquantel from poly(ε-caprolactone) implants. Int J Pharm, 2009, 377: 112-119.
2. Li C, Cheng L, Guo S, Wu WP. Effects of implant diameter, drug loading and end-capping on praziquantel release from PCL implants. Int J Pharm, 2010, 386: 23-29.
3. Cheng L, Lei L, Guo S. In vitro and in vivo evaluation of praziquantel loaded implants based on PEG/PCL blends. Int J Pharm, 2010, 387: 129-138.
程丽芳,博士,讲师。2010年毕业于江南大学食品科学与技术国家重点实验室,从事微生物源活性蛋白的基因重组、改造、及治疗性基因递送的相关研究。
1. Cheng L, Mu W, Zhang T, Jiang B. An L-arabinose isomerase from Acidothermus cellulolytics ATCC 43068: cloning, expression, purification and characterization. Appl Microbiol Biotechnol, 2010, 86(4):1089–1097.
2. Cheng L, Mu W, Zhang T, Jiang B. Cloning, expression and partial characterization of thermostable L-arabinose isomerase from Bacillus stearothermophilus IAM 11001 for D-tagatose preparation. J Biotechnol, 2008, 136S: S741–S742.
3. Cheng L, Mu W, Jiang B. Thermostable L-arabinose isomerase from Bacillus stearothermophilus IAM 11001 for D-tagatose production: gene cloning, purification and characterization. J Sci Food Agri, 2010, 90:1327–1333.